Nuwellis shares jump 89.97% after hours to $3.59 after FDA expands Aquadex FlexFlow indication
AI Market Summary
Nuwellis' shares surged after-hours after FDA expanded the Aquadex FlexFlow/SmartFlow indication to include adult and pediatric patients ≥20kg who are diuretic-unresponsive, alongside disclosure of preliminary Q2 revenue growth (+14% YoY; +20% over six months). The move reflects improved commercialization prospects and increased clinical adoption, though the company remains a micro-cap with elevated volatility and a deeply negative 12-month drawdown.
Impact level
● Low
Affected assets
NCSKS2USD/USDT+0.98%
AI Insight · NCSKS2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
U.S. medical technology company Nuwellis (NUWE) surged 89.97% in after-hours trading to $3.59 after its Aquadex FlexFlow system received an expanded indication from the FDA. The device can now be used for adult and pediatric patients weighing 20 kilograms or more whose condition has not responded to diuretics. The company also reported preliminary Q2 revenue growth of 14% year over year and 20% growth for the first six months. Nuwellis’ market capitalization is about $963,810, and the stock is down 99.49% from its 52-week high of $392.83.
